Topline data were announced from a phase 3 trial that evaluated baxdrostat in patients with uncontrolled or treatment resistant hypertension.

AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary ...

Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...

Research news of note last week included US biotech Crinetics Pharmaceuticals releasing new Phase III data on its acromegaly drug candidate Palsonify (paltusotine). AstraZeneca announced positive ...

At two doses, baxdrostat demonstrated significant reduction in mean seated systolic BP vs. placebo at 12 weeks among patients ...

AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial of the highly selective ASI, baxdrostat.

AstraZeneca AZN reported positive top-line results from a late-stage study evaluating the safety, tolerability and efficacy ...

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...

Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstraZeneca shares with a ...

AstraZeneca (AZN) on Monday said that its investigational drug Baxdrostat reduced systolic blood pressure (SBP) compared with ...

AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...

AstraZeneca (LSE:AZN) recently announced that its investigational antibody, anselamimab, did not achieve statistical ...